Incysus Seeks OK to Begin Phase 1 Trial of Gamma-delta T-cell Immunotherapy for Glioblastoma – Immuno-Oncology News
|
Incysus Seeks OK to Begin Phase 1 Trial of Gamma-delta T-cell Immunotherapy for Glioblastoma
Immuno-Oncology News Incysus has submitted its second investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial of its gamma-delta T-cell immunotherapy candidate for the treatment of glioblastoma. The … |
